Rizatriptan Benzoate Tablet
Product Images NDC 50090-3367

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 50090-3367). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500903367)

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

This is a graph displaying the probability of achieving an initial headache response within 2 hours after treatment with placebo, 5mg and 10mg doses of rizatriptan benzoate. The graph displays estimates based on pooled data from 4 outpatient clinical trials (Studies 1, 2, 3, and 4). The data only includes patients who achieved headache response or had mild/no pain within 2 hours after treatment. Patients who did not achieve headache response or were taking additional treatment were excluded from the data.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

This is a Figure 2 plot representing the estimated probability that patients will take a second dose of Rizatriptan Benzoate tablets or other medication for migraines within 24 hours following the initial dosage of the study treatment. The plot is based on data from different clinical trials (Studies 1, 2, 3, and 4) and shows that patients who took Rizatriptan Benzoate 5mg had a probability of 190% of taking a second dose while those who took 10mg had a probability of 180%. Patients not using additional treatments were excluded after 24 hours, and re-medication could not be done within 2 hours.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)

FDA Label Image

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.